You are not logged in.
Openly accessible

Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer

Deng, Junli, Wang, Li, Chen, Hongmin, Hao, Jingli, Ni, Jie, Chang, Lei, Duan, Wei, Graham, Peter and Li, Yong 2016, Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer, Oncotarget, vol. 7, no. 34, pp. 55771-55788, doi: 10.18632/oncotarget.9908.

Attached Files
Name Description MIMEType Size Downloads
duan-targetingepithelialmesenchy-2016.pdf Published version application/pdf 2.87MB 12

Title Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer
Author(s) Deng, Junli
Wang, Li
Chen, Hongmin
Hao, Jingli
Ni, Jie
Chang, Lei
Duan, WeiORCID iD for Duan, Wei orcid.org/0000-0001-5782-9184
Graham, Peter
Li, Yong
Journal name Oncotarget
Volume number 7
Issue number 34
Start page 55771
End page 55788
Total pages 18
Publisher Impact Journals
Place of publication Orchard Park, N.Y.
Publication date 2016-06-09
ISSN 1949-2553
Keyword(s) CSC
EMT
chemoresistance
metastasis
ovarian cancer
therapy
Summary Chemoresistance is the main challenge for the recurrent ovarian cancer therapy and responsible for treatment failure and unfavorable clinical outcome. Understanding mechanisms of chemoresistance in ovarian cancer would help to predict disease progression, develop new therapies and personalize systemic therapy. In the last decade, accumulating evidence demonstrates that epithelial-mesenchymal transition and cancer stem cells play important roles in ovarian cancer chemoresistance and metastasis. Treatment of epithelial-mesenchymal transition and cancer stem cells holds promise for improving current ovarian cancer therapies and prolonging the survival of recurrent ovarian cancer patients in the future. In this review, we focus on the role of epithelial-mesenchymal transition and cancer stem cells in ovarian cancer chemoresistance and explore the therapeutic implications for developing epithelial-mesenchymal transition and cancer stem cells associated therapies for future ovarian cancer treatment.
Language eng
DOI 10.18632/oncotarget.9908
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 929999 Health not elsewhere classified
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, Impact Journals
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30085984

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in TR Web of Science
Scopus Citation Count Cited 9 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 98 Abstract Views, 13 File Downloads  -  Detailed Statistics
Created: Wed, 07 Sep 2016, 14:38:34 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.